Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes

Table 2 Phase II studies on intraperitoneal chemotherapy using taxanes for the treatment of gastric cancer with peritoneal carcinomatosis

Ref.	n	Method	Intraperitoneally administered agents	MST (mo)	1-yr OS (%)	2-yr OS (%)	5-yr OS (%)
Yonemura et al[38]	61	NIPS	DOC (40 mg) + CBDCA (150 mg)	14.4	67
Ishigami et al[14]	40	SPIC	PTX (20 mg/m2)	22.6	78
Fujiwara et al[17]	18	NIPS	DOC (40-60 mg/m2)	24.6	76	54
Imano et al[39]	35	NIPS	PTX (80 mg/m2)	21.3	69	46	14
Yamaguchi et al[15]	35	SPIC	PTX (20 mg/m2)	17.6	77	45
Fushida et al[16]	27	SPIC	DOC (35-50 mg/m2)	16.2	70	33

MST: Median survival time; OS: Overall survival; DOC: Docetaxel; CBDCA: Carboplatin; PTX: Paclitaxel; NIPS: Neoadjuvant intraperitoneal and systemic chemotherapy; SPIC: Sequential perioperative intraperitoneal chemotherapy.